Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers
Open Access
- 3 March 2008
- journal article
- review article
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 2 (3) , 428-436
Abstract
The cerebrospinal fluid (CSF) circulates within the CNS where it plays an essential physiological role in homeostasis of neuronal cells. This biological fluid has an important protein diversity that results from both filtration of serum through the blood–brain barrier and production/secretion of neuronal peptides and proteins. Changes in CSF composition depend on blood proteome, CSF circulation alterations, as well as physiological or pathological brain status. Hence, CSF proteomic analysis gives a unique opportunity to detect and describe biomarkers in neurological affections. Although lumbar puncture is considered as invasive, post lumbar puncture events remain rare and minor. Nevertheless, CSF biological analysis is currently limited to a small number of parameters and clinical situations suggesting mainly meningitis, malignancies or dementia. Few CSF proteomic studies have been performed in comparison to those on blood. In this review, we will provide a proteomics description of the CSF, summarize the current clinical use of this fluid and describe its clinical proteomics examination.Keywords
This publication has 59 references indexed in Scilit:
- Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's diseaseBMC Neurology, 2007
- Proteomic Analysis of Cerebrospinal Fluid Changes Related to Postmortem IntervalClinical Chemistry, 2006
- Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography‐Fourier transform ion cyclotron resonance mass spectrometryProteomics, 2004
- Proteome analysis of cerebrospinal fluid proteins in Alzheimer patientsNeuroReport, 2002
- Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2001
- The Cerebrospinal Fluid Levels of Tau, Growth-Associated Protein-43 and Soluble Amyloid Precursor Protein Correlate in Alzheimer’s Disease, Reflecting a Common Pathophysiological ProcessDementia and Geriatric Cognitive Disorders, 2001
- Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasmaAmyloid, 2000
- Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob diseaseAnnals of Neurology, 1998
- Human brain S100β and S100β mRNA expression increases with age: Pathogenic implications for Alzheimer's diseaseNeurobiology of Aging, 1996
- Abnormal Proteins in the Cerebrospinal Fluid of Patients with Creutzfeldt–Jakob DiseaseNew England Journal of Medicine, 1986